What Is Xylazine and Why Does It Matter?

Xylazine is an alpha-2 adrenergic receptor agonist used as a sedative in veterinary medicine. It is not approved for human use. Beginning around 2019, illicit manufacturers began adulterating the fentanyl supply with xylazine to extend and intensify sedation — giving fentanyl what street users call "legs." The combination, known as "tranq dope," has spread with alarming speed. The DEA has seized fentanyl-xylazine mixtures in 48 of 50 states, and SAMHSA confirmed that xylazine was involved in approximately 11% of U.S. overdose deaths in 2022, up from near zero in 2015. By 2023, approximately 30% of fentanyl powder samples seized by the DEA contained xylazine. The White House Office of National Drug Control Policy formally designated fentanyl mixed with xylazine as an emerging threat to the United States in April 2023 — the first time that designation had ever been used.

The clinical picture is severe. Xylazine causes profound sedation, a withdrawal syndrome that does not respond to opioid medications, and characteristic necrotic skin wounds that develop regardless of the route of administration. SAMHSA has issued direct guidance to addiction treatment providers about managing xylazine exposure, emphasizing that standard opioid treatment protocols are insufficient when xylazine is part of the patient's drug use history.

Why Standard Panels Miss Xylazine — and What to Do About It

Standard immunoassay drug panels were designed to detect opiates, stimulants, benzodiazepines, THC, and PCP — the drug classes that historically drove treatment admissions. Xylazine operates on an entirely different receptor pathway and does not trigger any standard panel analyte. A client arriving at intake with fentanyl-xylazine exposure will appear clean on a standard 10-panel or 12-panel screen. SAMHSA's guidance explicitly identifies point-of-care xylazine testing as a key tool for clinical awareness in treatment and harm reduction settings — and for good reason. Without a dedicated xylazine screen, treatment teams cannot accurately assess withdrawal risk, wound care needs, or medication protocol appropriateness for clients who have been using tranq dope.

The practical solution is straightforward: add a standalone xylazine drug test strips dip card to your existing intake screening protocol. Run it alongside your standard multi-panel urine cup. Read the result in five minutes. Document it in the client's intake toxicology record. For programs looking to buy xylazine test kits for rehab centers or order bulk xylazine testing supplies for recovery facilities, DrugScreens.com ships single-panel xylazine dip cards to treatment programs nationwide with volume pricing and same-day shipping on qualifying orders.